Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Amorphous taclolimus solid dispersion having an enhanced solubility and pharmaceutical composition comprising same

A technology of solid dispersion and tacrolimus, which can be used in pharmaceutical combinations, organic active ingredients, medical preparations containing active ingredients, etc., and can solve problems such as low bioavailability

Inactive Publication Date: 2008-01-30
HANMI PHARMA
View PDF1 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thus, when water-insoluble tacrolimus is orally administered, its bioavailability is inevitably low

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Amorphous taclolimus solid dispersion having an enhanced solubility and pharmaceutical composition comprising same
  • Amorphous taclolimus solid dispersion having an enhanced solubility and pharmaceutical composition comprising same
  • Amorphous taclolimus solid dispersion having an enhanced solubility and pharmaceutical composition comprising same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] 400 mg of 2-hydroxypropyl-β-cyclodextrin (Aldrich, USA), 20 mg of citric acid and 20 mg of Poloxamer (Poloxamer) 188 (Lutrol F68, BASF) were added to MC (dichloromethane) and ethanol and stirred until the solution became clear. Then, 400 mg of lactose was added thereto and dispersed evenly. 100 mg of tacrolimus dissolved in ethanol was mixed with the dispersion and spray-dried while the inlet and outlet temperatures of the spray dryer (mini spray dryer B-191, Buchi, Switzerland) were maintained at 60 °C, respectively. °C and 45-50 °C to obtain a solid dispersion of tacrolimus with the ingredients listed in Table 1.

Embodiment 2

[0065] A tacrolimus solid dispersion having the ingredients listed in Table 1 was prepared by repeating the procedure of Example 1 except that 200 mg of 2-hydroxypropyl-β-cyclodextrin was used.

Embodiment 3

[0067] A tacrolimus solid dispersion having the ingredients listed in Table 1 was prepared by repeating the procedure of Example 1 except that 800 mg of 2-hydroxypropyl-β-cyclodextrin was used.

[0068] Table 1

[0069]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An amorphous solid dispersion of tacrolimus comprising tacrolimus, a substituted cyclodextrin derivative and an organic acid, the solid dispersion having high thermodynamic stability and solubility, providing enhanced release rate and bioavailability.

Description

technical field [0001] The present invention relates to an amorphous tacrolimus solid dispersion comprising tacrolimus, a substituted cyclodextrin derivative and an organic acid and a pharmaceutical composition comprising the dispersion, the solid dispersion exhibiting Enhanced bioavailability of tacrolimus. Background technique [0002] Molecular formula (I) is (-)-(1R, 9S, 13R, 14S, 17R, 18E, 21S, 23S, 24R, 25S, 27R)-17-allyl-1,14-dihydroxyl-12-[( E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl]-23,25-dimethoxy-13,19,21,27 -Tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0 4.9 ] Tacrolimus (or FK-506) of octacos-18-ene-2,3,10,16-tetraketone hydrate [104987-11-3] was proposed by Tanaka and Kuroda et al. (see J. Microlide-based immunosuppressive drugs discovered in Am. Chem. Soc., 109:5031 (1987) and US Pat. No. 4,894,366). [0003] [0004] The U.S. Food and Drug Administration has approved tacrolimus for the suppression of transplant rejection (Prograf) ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D498/18
CPCA61K9/1652A61K9/4858A61K9/1635A61K9/1617A61K9/4866A61K31/436A61K9/1641C07D498/18A61K9/1623A61P11/08A61P13/12A61P17/14A61P19/02A61P27/02A61P37/00A61P43/00A61P3/10C07D491/18
Inventor 禹钟守李鸿基朴贞姬
Owner HANMI PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com